Are you attending the upcoming Hanson Wade Group’s ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit from September 9-10 in Boston? Don’t miss the two talks by our CBO, Ingo Lehrke: On September 9 at 4:20 pm, he will give a presentation on how Tubulis aims to expand the therapeutic potential of ADCs with our set of proprietary platform technologies, including an update on our clinical development programs and our next steps in seeking new conjugates for our differentiated SolidTumor pipeline.
On September 10 at 8:15 am, Ingo will participate in a panel discussion on the relevance and potential of antibody-drug conjugation in the context of protein degradation.
Find the full agenda details here.
